An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study (MILESTONE℠)
Phase of Trial: Phase III
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Fampridine (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms MILESTONE
- Sponsors Acorda Therapeutics
- 14 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 07 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2015 New trial record